文献速递类风湿关节炎

甲氨蝶呤在早期类风湿关节炎联合治疗中的安全性与疗效:一项随机对照试验的事后分析

Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2024-01-18

该事后分析纳入NORD-STAR试验中812例未接受过治疗的早期类风湿关节炎患者,随机接受甲氨蝶呤联合积极传统治疗、培塞利珠单抗、阿巴西普或托珠单抗。与积极传统治疗相比,甲氨蝶呤联合托珠单抗时副作用发生率更高(HR 1.48,95%CI 1.20-1.84),联合培塞利珠单抗或阿巴西普时无显著差异。甲氨蝶呤剂量在联合托珠单抗或阿巴西普时显著更低,但在各联合方案中剂量减少均未伴随CDAI缓解率下降。

要点

  • 甲氨蝶呤联合托珠单抗时副作用发生率高于积极传统治疗(HR 1.48,95%CI 1.20-1.84)。
  • 甲氨蝶呤剂量在联合托珠单抗(β -4.65,P<0.001)或阿巴西普(β -1.15,P=0.04)时显著低于积极传统治疗。
  • 各治疗组合中甲氨蝶呤剂量减少均未伴随CDAI缓解率下降。

核心结论

  • 甲氨蝶呤在联合治疗中总体耐受良好,但不良事件是达到目标剂量25 mg/周的限制因素,且联合托珠单抗时较积极传统治疗更频繁。
  • 在四种治疗组合中,24周时甲氨蝶呤剂量减少均未伴随CDAI缓解率下降。

研究设计与样本

  • NORD-STAR随机对照试验的事后分析,纳入812例未接受过治疗的早期类风湿关节炎患者,按1:1:1:1随机接受甲氨蝶呤联合积极传统治疗、培塞利珠单抗、阿巴西普或托珠单抗。
  • 评估治疗24周后的甲氨蝶呤安全性、剂量及剂量对CDAI缓解的影响。

主要发现

  • 与积极传统治疗相比,甲氨蝶呤联合托珠单抗时甲氨蝶呤相关副作用发生率更高(HR 1.48,95%CI 1.20-1.84),联合培塞利珠单抗(HR 0.99,95%CI 0.79-1.23)或阿巴西普(HR 0.93,95%CI 0.75-1.16)时无显著差异。
  • 以积极传统治疗为参照,甲氨蝶呤剂量在联合托珠单抗时显著更低(β -4.65,95%CI -5.83至-3.46;P<0.001),联合阿巴西普时显著更低(β -1.15,95%CI -2.27至-0.03;P=0.04),联合培塞利珠单抗时数值上更低(β -1.07,95%CI -2.21至0.07;P=0.07)。
  • 在任何治疗组合中,甲氨蝶呤剂量减少均与CDAI缓解率下降无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We investigated methotrexate safety and the influence of dose on efficacy outcomes in combination with three different biologic treatments and with active conventional treatment (ACT) in early rheumatoid arthritis (RA). METHODS: This post hoc analysis included 812 treatment-naïve patients with early RA who were randomized (1:1:1:1) in the NORD-STAR trial to receive methotrexate in combination with ACT, certolizumab-pegol, abatacept, or tocilizumab. Methotrexate safety, doses, and dose effects on Clinical Disease Activity Index (CDAI) remission were assessed after 24 weeks of treatment. RESULTS: Compared with ACT, the prevalence of methotrexate-associated side effects was higher when methotrexate was combined with tocilizumab (hazard ratio [HR] 1.48, 95% confidence interval [CI] 1.20-1.84) but not with certolizumab-pegol (HR 0.99, 95% CI 0.79-1.23) or with abatacept (HR 0.93, 95% CI 0.75-1.16). With ACT as the reference, the methotrexate dose was significantly lower when used in combination with tocilizumab (β -4.65, 95% CI -5.83 to -3.46; P < 0.001) or abatacept (β -1.15, 95% CI -2.27 to -0.03; P = 0.04), and it was numerically lower in combination with certolizumab-pegol (β -1.07, 95% CI -2.21 to 0.07; P = 0.07). Methotrexate dose reductions were not associated with decreased CDAI remission rates within any of the treatment combinations. CONCLUSION: Methotrexate was generally well tolerated in combination therapies, but adverse events were a limiting factor in receiving the target dose of 25 mg/wk, and these were more frequent in combination with tocilizumab versus ACT. On the other hand, methotrexate dose reductions were not associated with decreased CDAI remission rates within any of the four treatment combinations at 24 weeks.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Lend K, Koopman FA, Lampa J, et al. Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial. Arthritis Rheumatol. 2024. PMID: 37846618. doi:10.1002/art.42730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。